JSPRJasper Therapeutics Inc

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS) sharesread more...

Major M&A deals this week include: New Mountail Capital buys Asset Living, SalesForce acquires Contentful, Wellington nabs The Hartford Fundsread more...

Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.

AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.

AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totaling 3,455,246 shares, a...

Beyond Meat, Bitfarms, Fitell, Eventbrite, and Jasper Therapeutics are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small...

Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic asthma treatment.read more...